The anticoagulant properties of different heparin fractions
Bychko, S.M.; Kharlamova, V.N.
Biulleten' Eksperimental'noi Biologii i Meditsiny 79(2): 61-63
1975
ISSN/ISBN: 0365-9615 PMID: 1131415 Document Number: 88242
Document emailed within 1 workday
Related Documents
Krupiński, K.; Bielawiec, M.; Breddin, H.K. 1994: Antithrombotic properties of heparin independent of its anticoagulant activity Acta Haematologica Polonica 25(3): 243-251Byshevskiĭ, A.S.; Sokolovskiĭ, S.R. 1982: Potentiation of the anticoagulant effects of a phosphatidylserine-containing anticoagulant and heparin Voprosy Meditsinskoi Khimii 28(2): 30-34
Bychkov, S.M.; Kharlamova, V.N. 1976: Different heparin fractions Biulleten' Eksperimental'noi Biologii i Meditsiny 81(3): 289-291
Dalmora, S.L.; Assaf, G.S.; Dalmora, M.E.; Vaucher, L.C.; Vaccari, S.F. 1991: Determination of anticoagulant activity of heparin Revista do Hospital das Clinicas 46(2): 59-62
Mazaev, A.V.; Sargin, K.E. 1986: Clinical use of heparin and its low-molecular fractions Kardiologiia 26(9): 122-125
Bremmelgaard, A. 1986: Heparin and monitoring of peroral anticoagulant therapy Ugeskrift for Laeger 148(21): 1275-1276
Ofosu, F.A. 1988: Mechanisms for the anticoagulant effect of heparin and related polysaccharides Nouvelle Revue Francaise d'Hematologie 30(3): 155-160
Graham, D.T.; Pomeroy, A.R. 1980: Relative activities of heparin fractions obtained by gel chromatography Thrombosis and Haemostasis 42(5): 1598-1603
Matsuoka, T.; Inoue, K.; Mizuno, K.; Kita, Y.; Nakanishi, S.; Asai, S.; Taoka, R.; Soda, T.; Terai, A. 2012: Heparin as bridging anticoagulant and antiplatelet therapy during the perioperative period Hinyokika Kiyo. Acta Urologica Japonica 58(5): 223-226
Millot, F.; Bara, L.; Etienne, J.; Samama, M.; Laruelle, P. 1987: Lipolytic and anticoagulant activities of heparin and one of its low molecular weight derivatives Nouvelle Revue Francaise d'Hematologie 29(6): 397-400
Kudriashov, B.A.; Liapina, L.A.; Azieva, L.D. 1990: The content of a heparin-like anticoagulant in the flowers of the meadowsweet (Filipendula ulmaria) Farmakologiia i Toksikologiia 53(4): 39-41
Sawada, S.; Yamamoto, A.; Sudo, H.; Yamashita, H. 1979: Heparin-Ca turbidimetric quantitation of the serum lipoprotein fractions in hyperlipidemia Rinsho Byori. Japanese Journal of Clinical Pathology 27(9): 835-838
Strukova, S.M.; Khlebnikova, T.G.; Umarova, B.A.; Kulibali, M. 1984: Heparin secretion by mast cells as an index of the status of the anticoagulant system Biulleten' Eksperimental'noi Biologii i Meditsiny 97(2): 131-134
Giannitsis, D.J. 1978: Neutralising effect of histone fractions from human leukocyte nuclei on heparin Arzneimittel-Forschung 28(11): 2158-2159
Burg, M.; Ostendorf, T.; Mooney, A.; Koch, K.M.; Floege, J. 1997: Treatment of experimental mesangioproliferative glomerulonephritis with non-anticoagulant heparin: therapeutic efficacy and safety Laboratory Investigation; A Journal of Technical Methods and Pathology 76(4): 505-516
Shammas, N.W.; Lemke, J.H.; Dippel, E.J.; McKinney, D.E.; Takes, V.S.; Youngblut, M.; Harris, M.; Harb, C.; Kapalis, M.J.; Holden, J. 2003: In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant Journal of Invasive Cardiology 15(5): 242-246
Völker, W.; Böhm, A.; Schmidt, A.; Svahn, C.M.; Gellerbring, A.K.; Mattsson, C.; Ekvärn, S.; Robenek, H.; Buddecke, E. 1995: Inhibition of smooth muscle cell proliferation and neointimal growth by low-anticoagulant heparin Arzneimittel-Forschung 45(5): 546-550
Schneider, T.; Heuer, B.; Deller, A.; Boesken, W.H. 2000: Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocytopenia (HIT II) Wiener Klinische Wochenschrift 112(12): 552-555
Barrowcliffe, T.W.; Le Shirley, Y. 1989: The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions Thrombosis and Haemostasis 62(3): 950-954
Harenberg, J.; Stehle, G.; Dempfle, C.E.; von Hodenberg, E.; Heene, D.L. 1989: The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects Folia Haematologica 116(6): 967-980